Peer-reviewed veterinary case report
Risk factors for kidney problems in cats with cancer on doxorubicin
By Kopecny, Lucy et al.·Published in Journal of veterinary internal medicine·2020·Department of Veterinary Medicine and Epidemiology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Risk factors associated with progressive increases in serum creatinine concentrations in cats with cancer receiving doxorubicin.
- Species:
- cat
Plain-English summary
A group of 70 cats with cancer, including types like lymphoma and sarcoma, were treated with doxorubicin, a chemotherapy drug. Some of these cats developed kidney issues, with about 34% showing a significant increase in a blood marker called serum creatinine, which can indicate kidney problems. Factors like having low white blood cells or red blood cells during treatment and the number of anesthesia sessions for radiation therapy were linked to these kidney increases. Cats receiving doxorubicin alone were more likely to experience these kidney issues compared to those on a combination chemotherapy protocol. Monitoring kidney function is important for cats undergoing this treatment.
People also search for: cat cancer treatment doxorubicin side effects · cat kidney problems after chemotherapy · lymphoma in cats treatment options
Abstract
BACKGROUND: Azotemia occurs in cats administered doxorubicin, but risk factors have not been explored. OBJECTIVE: To determine incidence of progressive increases in serum creatinine concentration in cats with cancer receiving doxorubicin in single or multiagent chemotherapy protocols and associated risk factors. ANIMALS: Seventy cats with cancer receiving doxorubicin. METHODS: A retrospective study (2007-2017) of cats with indices of kidney function recorded before and after doxorubicin administration was reviewed. Cats diagnosed with kidney injury because of known etiologies other than possible doxorubicin toxicosis were excluded. Variables were compared to identify risk factors. RESULTS: Mean age (±SD) was 10.9 years (±3.2). Cancer types included lymphoma (n = 36), sarcoma (n = 19) and carcinoma (n = 14). Chronic kidney disease was present in 29/70 (41%) cats before receiving doxorubicin. Of 70 cats, 24 (34%) developed an increase in serum creatinine concentration ≥0.3 mg/dL and 10 (14%) had an increase ≥50% from baseline. Mean time to increases in serum creatinine concentration ≥0.3 mg/dL from first administration of doxorubicin was 119.3 days (±89.7), with mean 2.8 (±1.2) doses administered. Neutropenia or anemia during chemotherapy and number of radiation therapy treatments under general anesthesia were risk factors for increases in serum creatinine concentration (P < .05). Cats receiving single agent doxorubicin had a higher likelihood of an increase in serum creatinine concentration ≥0.3 mg/dL from baseline than cats receiving CHOP-based chemotherapy protocols (OR 20.0, 95% CI 2.9-100). CONCLUSIONS AND CLINICAL IMPORTANCE: Progressive increases in serum creatinine concentration from baseline were common in cats receiving doxorubicin and associated risk factors were identified.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32779764/